VR

Virax Biolabs Group LtdNASDAQ VRAX Stock Report

Last reporting period 31 Mar, 2022

Updated 14 Nov, 2024

Last price

Market cap $B

0.008

Micro

Exchange

XNAS - Nasdaq

VRAX Stock Analysis

VR

Uncovered

Virax Biolabs Group Ltd is uncovered by Eyestock quantitative analysis.

Market cap $B

0.008

Dividend yield

Shares outstanding

11.663 B

Virax Biolabs Group Ltd. is a holding company. The firm is primarily engaged in the sales, distribution and marketing of diagnostics test kits and med-tech and personal protective equipment (PPE) products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear, ViraxCare, and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Its products include antigen tests, polymerase chain reaction (PCR) rapid tests, and neutralizing antibody tests. ViraxCare develops and distributes advanced medical devices, technology, and PPE globally. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus.

View Section: Eyestock Rating